The recent explosion of targeted agents available for study has generated enthusiasm for
oncologists treating thyroid cancer. Antiangiogenesis strategies in particular appear …

Background Anaplastic thyroid cancer has a median survival between 1.2 and 10 months.
The purpose of our study was to evaluate the outcomes of patients with anaplastic thyroid …

Background Anaplastic thyroid cancer (ATC) is a fatal endocrine malignancy. Current
therapy fails to significantly improve survival. Recent insights into thyroid tumorigenesis, post …

Background Questions exist regarding patient selection for surgery in anaplastic thyroid
carcinoma (ATC), particularly with the advent of neoadjuvant‐targeted therapeutics. The …

Background: The present study aims to evaluate the outcomes and toxicity of elderly
anaplastic thyroid cancer (ATC) patients receiving (chemo) radiotherapy, as well as to …

The therapeutic approach to thyroid carcinoma usually involves surgery as initial treatment.
The use of external beam radiotherapy (EBRT) is limited to high-risk patients and depends …

New therapeutic approaches are mandatory for anaplastic thyroid cancer. We investigated
the ability of a new combined treatment using valproic acid (VPA), the only clinically …

Thyroid cancer is the endocrine tumor that bears the highest incidence with 33 550 new
cases per year. It bears an excellent prognosis with a mortality of 1530 patients per year …

Purpose Little is known about prognostic factors and treatment outcomes in young patients
with anaplastic thyroid cancer (ATC). The goal of this study is to define the clinical features of …

Anaplastic thyroid carcinoma (ATC)(less than 10% of all thyroid cancer) is a high-grade
neoplasm, characterized by an aggressive clinical course and refractoriness to currently …